Royalty Report: Drugs, Wound Care, Therapeutic – Collection: 294703

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Wound Care
  • Therapeutic
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 294703

License Grant
Israelite Licensor has agreed to reduce the contingent consideration that is payable to Licensor pursuant to the exercised rights by the Licensee to repurchase all shares held by the Licensor in consideration for future sales-based royalty payments from products or license of NexoBrid.
License Property
NexoBrid is for treatment of connective tissue disorders and other indicationse including for the treatment of severe burns.

NexoBrid™ contains a mixture of enzymes called “concentrate of proteolytic enzymes enriched in bromelain”, which is extracted from the stem of the pineapple plant.

Field of Use
NexoBridâ„¢ is indicated for the removal of eschar in adults with deep partial- and full-thickness thermal burns, a process also known as debridement.

IPSCIO Record ID: 264136

License Grant
The Licensor, an individual, hereby grants to Israelis Licensee with effect from the Effective Date subject to the terms of this Agreement, an exclusive license under and using the Intellectual Property and Improvements for the purpose of developing, using, marketing, supplying and selling the Product in the Territory, with the right to sub-license.
License Property
Licensor is the owner of certain patents and proprietary information and know-how relating to a pharmaceutical product known as debridase, based on Bromelain which product may be used for debriding bums and other wounds.

“Bromelain” means the raw material derived from pineapple sterns and specially processed for the Product.

NexoBrid has been designated an orphan drug and for the treatment of severe burns.  NexoBrid’s label provides that it only be used in specialized burns centers or by burn specialists

NexoBrid is an easy to use, topically-applied product that removes eschar in four hours without harming the surrounding healthy tissues. The removal of eschar is a procedure also known as debridement. Debridement is a critical first step in the successful healing of severe burns and chronic and other hard-to-heal wounds. Under existing SOC, burn eschar may be removed either by employing certain existing topical agents that have been found to be minimally effective or that take a significantly longer period of time to work, or by resorting to non-selective surgery, which is traumatic and may result in loss of blood and viable tissue. NexoBrid’s rapid and selective debridement alleviates the known risks associated with eschar, such as infection, eventual sepsis, wound deterioration and consequential scarring, and it allows physicians to reach an informed decision on further treatment at an earlier stage by direct visual assessment of the actual burn depth. Furthermore, NexoBrid minimizes the burden associated with invasive surgical procedures, reduces the need for skin grafting and sacrifice of healthy tissue from donor sites on a patient’s body and generally results in a more favorable overall long-term patient outcome. NexoBrid has been investigated in hundreds of patients across more than 15 countries and four continents in seven completed Phase 2 and Phase 3 clinical studies

The claims of such patents are directed to a process of preparing a mixture of escharase and proteolytic enzymes and cover the underlying proteolytic mixture of escharase and proteolytic enzymes prepared by that specific process.

US Patent No 5, 830,739

Field of Use
Field” means the treatment of all forms of burns and other wounds in humans by way of debriding with debridase or other products derived using the Technology.

This agreement pertains to the drug industry relating in the fields of severe burns as well as chronic and other hard-to-heal wounds and connective tissue disorders.

IPSCIO Record ID: 4455

License Grant
The Israeli Licensor, an individual, grants the Licensee an exclusive license under and using the Intellectual Property and Improvements for the purpose of developing, using, manufacturing, having manufactured, marketing, supplying and selling the Product in the Territory, with the right to sub- license.
License Property
The Intellectual Property includes certain patents and proprietary information and know-how relating to a pharmaceutical product known as debridase, based on Bromelain, which product may be used for deriding bums and other wounds.

Bromelain means the raw material derived from pineapple sterns and specially processed for the Product.

Australia
AU 676464B2, ( the 464B2 Patent), examined and accepted, published March 13, 1997

Europe
EP618811B1, ( the 811B1 patent), granted patent Published April 5, 2000

Finland
F1942603A the (603A application), unexamined Published August 2, 1994

Hungary
HU21641B, the (641B patent), patent specification, Published on April 28, 1998

Israel
IL103969a, (the 969A patent), accepted application Open for Inspection, published January 10, 1997

Japan
JP08508635A (the 635A application) unexamined Published September 17, 1996 (Exhibit C)

USA
US Patent No 5, 830,739 issued November 3, 1998 (Exhibit D)

Field of Use
“Field” means the treatment of all forms of burns and other wounds in humans by way of debriding with debridase or other products derived using the Technology.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.